Investment Highlights Photocure holds a strong position in the field of bladder cancer with solid growth plans and ambition to expand its footprint. A commercial-stage company focused on bladder cancer Hexvix®/Cysview® is a product for the detection of bladder cancer: In excess of USD 40M global in market sales Specialist salesforce established in the U.S. and European region and additional emerging operations in other high-value territories through our partners, Juno Pharmaceuticals (Australia/New Zealand), and BioSyent Pharma (Canada). Value-building opportunity Large untapped potential for Hexvix®/Cysview® in existing and new market segments/territories FDA approval of Cysview® for use with flexible cystoscope Clarity on reimbursement for Cysview® in the U.S. Exploring expansion of bladder cancer portfolio to leverage commercial infrastructure Newsletter Subscribe to get the latest news when they are published Subscribe Unsubscribe Privacy policy Terms of use Follow Us Norway PHOTOCURE ASA Hoffsveien 4 0275 Oslo Norway Phone: +47 22 06 22 10 Fax: +47 22 06 22 18 Mail: info@photocure.no www.hexvix.com United States PHOTOCURE INC 104 Carnegie Center Suite 303 Princeton, NJ 08540 USA Phone: +1 609 759 6500 Fax: +1 609 799 0816 Mail: info@photocure.com www.cysview.com